| [1] |
Xia R, Zhou Y, Wang Y, et al. Hepatoid adenocarcinoma of the stomach: current perspectives and new developments[J]. Front Oncol, 2021, 11: 633916.
|
| [2] |
Meng W, Bai B, Bai Z, et al. The immunosuppression role of alpha-fetoprotein in human hepatocellular carcinoma[J]. Discov Med, 2016, 21(118): 489-494.
|
| [3] |
Zhang C, Zhang J, Wang J, et al. Alpha-fetoprotein accelerates the progression of hepatocellular carcinoma by promoting Bcl-2 gene expression through an RA-RAR signalling pathway[J]. J Cell Mol Med, 2020, 24(23): 13804-13812.
|
| [4] |
Bourreille J, Metayer P, Sauger F, et al. Existence of alpha feto protein during gastric-origin secondary cancer of the liver[J]. Presse Med (1893), 1970, 78(28): 1277-1278.
|
| [5] |
Ishikura H, Fukasawa Y, Ogasawara K, et al. An AFP-producing gastric carcinoma with features of hepatic differentiation. A case report[J]. Cancer, 1985, 56(4): 840-848.
|
| [6] |
Zhang Y, Han S, Lv L, et al. Case report: A rare case of hepatoid adenocarcinoma in stomach and duodenum simultaneously[J]. Cancer Manag Res, 2022, 14: 2185-2191.
|
| [7] |
Zhou Q, Zhou Y, Ouyang Y, et al. Hepatoid adenocarcinoma of the stomach with metastatic choriocarcinoma of the liver: A case report of a rare subtype of gastric cancer with a complex treatment course[J]. Front Surg, 2022, 9: 968891.
|
| [8] |
Osada M, Aishima S, Hirahashi M, et al. Combination of hepatocellular markers is useful for prognostication in gastric hepatoid adenocarcinoma[J]. Hum Pathol, 2014, 45(6): 1243-1250.
|
| [9] |
王祥旭, 潘伟, 博伦, 等. 35例胃肝样腺癌的临床病理观察[J]. 临床肿瘤学杂志, 2021, 26(3): 243-247.
|
| [10] |
赵荣飞, 王鑫鑫, 蓝忻, 等. 胃肝样腺癌临床病理特征及预后分析[J]. 中华胃肠外科杂志, 2017, 20(9): 1035-1039.
|
| [11] |
任为正, 苏茂生, 杜晓霞, 等. 胃肝样腺癌25例[J]. 中华肝胆外科杂志, 2016, 22(10): 665-667.
|
| [12] |
Liu XM, Chen GQ, Li SL, et al. Hepatoid adenocarcinoma of the stomach: A case report and literature review[J]. Exp Ther Med, 2015, 9(6): 2133-2136.
|
| [13] |
Su JS, Chen YT, Wang RC, et al. Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma: A literature review[J]. World J Gastroenterol, 2013, 19(3): 321-327.
|
| [14] |
张琛琛, 于伟华, 杜亚婷, 等. 胃肝样腺癌的临床病理特点及预后分析[J]. 中国现代普通外科进展, 2022, 25(7): 543-547.
|
| [15] |
Wang Y, Sun L, Li Z, et al. Hepatoid adenocarcinoma of the stomach: A unique subgroup with distinct clinicopathological and molecular features[J]. Gastric Cancer, 2019, 22(6): 1183-1192.
|
| [16] |
Chen EB, Wei YC, Liu HN, et al. Hepatoid adenocarcinoma of stomach: emphasis on the clinical relationship with alpha-fetoprotein-positive gastric cancer[J]. Biomed Res Int, 2019, 2019: 6710428.
|
| [17] |
Inoue M, Sano T, Kuchiba A, et al. Long-term results of gastrectomy for alpha-fetoprotein-producing gastric cancer[J]. Br J Surg, 2010, 97(7): 1056-1061.
|
| [18] |
Lin JX, Wang ZK, Hong QQ, et al. Assessment of clinicopathological characteristics and development of an individualized prognostic model for patients with hepatoid adenocarcinoma of the stomach[J]. JAMA Netw Open, 2021, 4(10): e2128217.
|
| [19] |
邵国益, 张献, 胡根, 等. AFP阳性胃肝样腺癌15例临床分析[J]. 现代肿瘤医学, 2015, 23(21): 3154-3157.
|
| [20] |
李晨, 夏绍友, 张勇. 胃肝样腺癌血清甲胎蛋白阳性的临床意义[J]. 中国医药导报, 2012, 9(6): 43-45, 48.
|
| [21] |
Lin Y, Yang Y, Li W, et al. Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells[J]. Mol Cell, 2012, 48(4): 627-640.
|
| [22] |
Zhao QW, Zhou YW, Li WX, et al. Akt-mediated phosphorylation of Oct4 is associated with the proliferation of stem-like cancer cells[J]. Oncol Rep, 2015, 33(4): 1621-1629.
|
| [23] |
Zhu M, Guo J, Li W, et al. HBx induced AFP receptor expressed to activate PI3K/AKT signal to promote expression of Src in liver cells and hepatoma cells[J]. BMC Cancer, 2015, 15: 362.
|
| [24] |
Li MS, Li PF, He SP, et al. The promoting molecular mechanism of alpha-fetoprotein on the growth of human hepatoma Bel7402 cell line[J]. World J Gastroenterol, 2002, 8(3): 469-475.
|
| [25] |
Li M, Mei YX, Wen JH, et al. Hepatoid adenocarcinoma-clinicopathological features and molecular characteristics[J]. Cancer Lett, 2023, 559: 216104.
|
| [26] |
Gálvez-Muñoz E, Gallego-Plazas J, Gonzalez-Orozco V, et al. Hepatoid adenocarcinoma of the stomach - a different histology for not so different gastric adenocarcinoma: A case report[J]. Int Semin Surg Oncol, 2009, 6: 13.
|
| [27] |
陆泳言, 姜文凯, 李硕, 等. 甲胎蛋白阳性胃癌的分子机制与诊疗现状[J]. 临床与病理杂志, 2022, 42(9): 2255-2261.
|
| [28] |
Rajasekaran P, Pattnaik B, Mishra M, et al. Alpha-fetoprotein (AFP)-negative hepatoid adenocarcinoma of the stomach and its associated uncommon features with a review[J]. Int J Surg Pathol, 2022: 10668969221142038.
|
| [29] |
Nagai E, Ueyama T, Yao T, et al. Hepatoid adenocarcinoma of the stomach. A clinicopathologic and immunohistochemical analysis[J]. Cancer, 1993, 72(6): 1827-1835.
|
| [30] |
于丽丽, 何向蕾, 吴建宇, 等. GPC3、HSP70、SALL4和AFP联合表达对胃肝样腺癌诊断的意义[J]. 浙江医学, 2020, 42(8): 780-782, 786, 884.
|
| [31] |
刘鑫, 温宗华, 张国, 等. 胃肝样腺癌6例临床资料分析[J]. 临床消化病杂志, 2017, 29(3): 155-158.
|
| [32] |
Metzgeroth G, Ströbel P, Baumbusch T, et al. Hepatoid adenocarcinoma-review of the literature illustrated by a rare case originating in the peritoneal cavity[J]. Onkologie, 2010, 33(5): 263-269.
|
| [33] |
Chen Y, Qu H, Jian M, et al. High level of serum AFP is an independent negative prognostic factor in gastric cancer[J]. Int J Biol Markers, 2015, 30(4): e387-e393.
|
| [34] |
Lin HJ, Hsieh YH, Fang WL, et al. Clinical manifestations in patients with alpha-fetoprotein-producing gastric cancer[J]. Curr Oncol, 2014, 21(3): e394-e399.
|
| [35] |
He F, Fu Y, Sun Q, et al. Integrated clinicopathological and immunohistochemical analysis of gastric adenocarcinoma with hepatoid differentiation: An exploration of histogenesis, molecular characteristics, and prognostic markers[J]. Hum Pathol, 2021, 115: 37-46.
|